BRISTOL-MYERS SQUIBB CO
2,660 institutions still hold BRISTOL-MYERS SQUIBB CO as of Q1 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
BMY Q1 2026 institutional ownership is a $93.6B book across 2,456 holders. BlackRock is the largest holder at $10.4B (171.7M shares, -1.6%, -$875M but still #1). Vanguard Capital Management is second at $8.1B (132.3M shares, NEW after three-way split). State Street is third at $6.0B (98.6M shares, +0.7%, +$693M). JPMorgan is fourth at $5.5B (92.5M shares, +72.3%, +$1.5B) -- the largest buyer. Charles Schwab is fifth at $3.7B (61.1M shares, -16.5%, -$141M). Geode Capital $3.3B (+5.8%, +$507M). Vanguard Portfolio Management $2.8B (NEW after split); Vanguard Fiduciary Trust $699M (NEW after split). Bank of America $2.0B (+175.3%, +$1.2B from $812M) -- explosive add. AQR Capital $1.8B (+22.7%, +$406M). Morgan Stanley $1.8B (+3.7%, +$242M). Ameriprise $1.6B (-5.7%, -$92M). Primecap $1.5B (+5.8%, +$174M). Northern Trust $1.5B (+0.7%, +$175M). BNY Mellon $1.4B (-3.1%, -$92M). UBS AM $1.4B (+26.0%, +$222M). Independent Franchise Partners $1.3B (+3.7%, +$167M). Dimensional Fund Advisors $1.1B (+3.2%, +$154M). Pzena Investment $1.0B (-4.2%, -$69M). Legal & General $1.0B (-2.3%, -$87M). Invesco $941M (-3.2%, -$33M). Two Sigma NEW $703M (11.6M shares vs $26M prior). New positions: Vanguard three-way; Bank of America $2.0B; Two Sigma $703M. Sellers: Susquehanna -$187M (-18.1%), Arrowstreet -$389M (-55.3%), Charles Schwab -$141M, Goldman Sachs -$136M, Invesco -$33M, Ameriprise -$92M. The 75.50 whaleScore reflects AUM. Smart-money-signal read: BMY Q1 2026 holder flows are strongly net-bullish. JPMorgan +$1.5B, Bank of America +$1.2B, Two Sigma new $703M, AQR +$406M, and UBS +$222M represent meaningful conviction adds from top-tier active managers. The sellers (Arrowstreet -$389M, Susquehanna -$187M, Pzena -$69M) are smaller in aggregate than the buyers. Notably, Bank of America went from effectively $0 (not in prior top-holders) to $2.0B -- this is an extraordinary repositioning. The net read: bullish on Bristol-Myers Squibb -- active managers are adding across the board, with the only meaningful sellers being quant/hedge-fund strategies (Arrowstreet, Susquehanna) that may be rotating rather than expressing fundamental conviction.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.